Walvax Biotechnology Co., Ltd. (SHE: 300142)

Market Cap	18.17B
Revenue (ttm)	3.10B
Net Income (ttm)	122.37M
Shares Out	1.60B
EPS (ttm)	0.08
PE Ratio	148.47
Forward PE	66.82
Dividend	0.01 (0.09%)
Ex-Dividend Date	May 30, 2024

Volume	14,881,015
Average Volume	19,802,456
Open	11.34
Previous Close	11.34
Day's Range	11.16 - 11.52
52-Week Range	9.78 - 19.18
Beta	0.64
RSI	37.05
Earnings Date	Mar 22, 2025

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,388
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300142

Financial Performance

In 2023, Walvax Biotechnology's revenue was 4.11 billion, a decrease of -19.12% compared to the previous year's 5.09 billion. Earnings were 419.39 million, a decrease of -42.44%.